👤 Jong-Lyel Roh

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
4
Articles
3
Name variants
Also published as: J.-L. Roh, JK Roh,
articles
Xin Chen, Andrey S. Tsvetkov, Han-Ming Shen +66 more · 2024 · Autophagy · Taylor & Francis · added 2026-04-20
Macroautophagy/autophagy is a complex degradation process with a dual role in cell death that is influenced by the cell types that are involved and the stressors they are exposed to. Ferroptosis is an Show more
Macroautophagy/autophagy is a complex degradation process with a dual role in cell death that is influenced by the cell types that are involved and the stressors they are exposed to. Ferroptosis is an iron-dependent oxidative form of cell death characterized by unrestricted lipid peroxidation in the context of heterogeneous and plastic mechanisms. Recent studies have shed light on the involvement of specific types of autophagy (e.g. ferritinophagy, lipophagy, and clockophagy) in initiating or executing ferroptotic cell death through the selective degradation of anti-injury proteins or organelles. Conversely, other forms of selective autophagy (e.g. reticulophagy and lysophagy) enhance the cellular defense against ferroptotic damage. Dysregulated autophagy-dependent ferroptosis has implications for a diverse range of pathological conditions. This review aims to present an updated definition of autophagy-dependent ferroptosis, discuss influential substrates and receptors, outline experimental methods, and propose guidelines for interpreting the results.Abbreviation: 3-MA:3-methyladenine; 4HNE: 4-hydroxynonenal; ACD: accidentalcell death; ADF: autophagy-dependentferroptosis; ARE: antioxidant response element; BH2:dihydrobiopterin; BH4: tetrahydrobiopterin; BMDMs: bonemarrow-derived macrophages; CMA: chaperone-mediated autophagy; CQ:chloroquine; DAMPs: danger/damage-associated molecular patterns; EMT,epithelial-mesenchymal transition; EPR: electronparamagnetic resonance; ER, endoplasmic reticulum; FRET: Försterresonance energy transfer; GFP: green fluorescent protein;GSH: glutathione;IF: immunofluorescence; IHC: immunohistochemistry; IOP, intraocularpressure; IRI: ischemia-reperfusion injury; LAA: linoleamide alkyne;MDA: malondialdehyde; PGSK: Phen Green™ SK;RCD: regulatedcell death; PUFAs: polyunsaturated fatty acids; RFP: red fluorescentprotein;ROS: reactive oxygen species; TBA: thiobarbituricacid; TBARS: thiobarbituric acid reactive substances; TEM:transmission electron microscopy. Show less
no PDF DOI: 10.1080/15548627.2024.2319901
Fe
F Fadlallah, K Elshiwy, Y Elkeraie +1388 more · 2024 · World Journal of Clinical Oncology · added 2026-04-20
F Fadlallah, K Elshiwy, Y Elkeraie, Z Merjaneh, G Khoudari, MT Sarmini, M Gad, M Al-Husseini, A Saad, RL Siegel, KD Miller, NS Wagle, A Jemal, A Kumar, V Gautam, A Sandhu, K Rawat, A Sharma, L Saha, M Bretthauer, M Løberg, P Wieszczy, M Kalager, L Emilsson, K Garborg, M Rupinski, E Dekker, M Spaander, M Bugajski, Ø Holme, AG Zauber, ND Pilonis, A Mroz, EJ Kuipers, J Shi, MA Hernán, HO Adami, J Regula, G Hoff, MF Kaminski, S Shinji, T Yamada, A Matsuda, H Sonoda, R Ohta, T Iwai, K Takeda, K Yonaga, Y Masuda, H Yoshida, M Zajkowska, B Mroczko, GJ Poston, J Figueras, F Giuliante, G Nuzzo, AF Sobrero, JF Gigot, B Nordlinger, R Adam, T Gruenberger, MA Choti, AJ Bilchik, Cutsem EJ Van, JM Chiang, MI D'Angelica, GJ Chang, AM Kaiser, S Mills, JF Rafferty, WD Buie, JR Monson, MR Weiser, J Rafferty, AE Blackmore, MT Wong, CL Tang, BL Green, HC Marshall, F Collinson, P Quirke, P Guillou, DG Jayne, JM Brown, J Mar, A Anton-Ladislao, O Ibarrondo, A Arrospide, S Lázaro, N Gonzalez, M Bare, D Callejo, M Redondo, JM Quintana, S Kitano, M Inomata, J Mizusawa, H Katayama, M Watanabe, S Yamamoto, M Ito, S Saito, S Fujii, F Konishi, Y Saida, H Hasegawa, T Akagi, K Sugihara, T Yamaguchi, T Masaki, Y Fukunaga, K Murata, M Okajima, Y Moriya, Y Shimada, P Gavriilidis, K Katsanos, K Toritani, J Watanabe, K Nakagawa, Y Suwa, H Suwa, A Ishibe, M Ota, C Kunisaki, I Endo, T Matsuda, Y Sumi, K Yamashita, M Yamamoto, Y Matsuda, S Kanaji, T Oshikiri, T Nakamura, S Suzuki, Y Kakeji, RK Cleary, AM Morris, AL Halverson, KA Mirkin, AS Kulaylat, CS Hollenbeak, E Messaris, S Atallah, B Martin-Perez, M Albert, T deBeche-Adams, G Nassif, L Hunter, S Larach, MX Bjørn, SK Perdawood, Z Shen, Y Ye, Q Xie, K Jiang, S Wang, G Wang, Z Wang, Z Jiang, J Liu, J Zhao, J Li, A Arezzo, MA Bonino, F Ris, L Boni, E Cassinotti, DCC Foo, NF Shum, A Brolese, F Ciarleglio, DS Keller, R Rosati, Nardi P De, U Elmore, Romario U Fumagalli, MD Jafari, A Pigazzi, E Rybakov, M Alekseev, N Vettoretto, R Cirocchi, R Passera, E Forcignanò, M Morino, SH Park, HM Park, KR Baek, HM Ahn, IY Lee, GM Son, FA Vuijk, DE Hilling, JSD Mieog, AL Vahrmeijer, A Hiroishi, T Morimoto, K Horikoshi, Y Nakajima, KL Baglan, RC Frazier, D Yan, RR Huang, AA Martinez, JM Robertson, JG Letschert, JV Lebesque, Boer RW de, AA Hart, H Bartelink, JY Wo, CJ Anker, JB Ashman, NA Bhadkamkar, L Bradfield, DT Chang, J Dorth, J Garcia-Aguilar, D Goff, D Jacqmin, P Kelly, NB Newman, J Olsen, AC Raldow, E Ruiz-Garcia, KB Stitzenberg, CR Jr Thomas, QJ Wu, P Das, V Paroder, TJ Fraum, S Nougaret, I Petkovska, GM Rauch, H Kaur, C Bascoul-Mollevi, S Gourgou, C Borg, PL Etienne, E Rio, E Rullier, B Juzyna, F Castan, T Conroy, RR Bahadoer, EA Dijkstra, Etten B van, CAM Marijnen, H Putter, EM Kranenbarg, AGH Roodvoets, ID Nagtegaal, RGH Beets-Tan, LK Blomqvist, T Fokstuen, Tije AJ Ten, J Capdevila, MP Hendriks, I Edhemovic, A Cervantes, PJ Nilsson, B Glimelius, de Velde CJH van, GAP Hospers, P Goffredo, FF Quezada-Diaz, JJ Smith, A Cercek, CSD Roxburgh, P Strombom, LKF Temple, GM Nash, JG Guillem, PB Paty, R Yaeger, ZK Stadler, K Seier, M Gonen, NH Segal, DL Reidy, A Varghese, J Shia, E Vakiani, AJ Wu, CH Crane, MJ Gollub, LB Saltz, V Vendrely, J Asselineau, P Rouanet, JJ Tuech, A Valverde, Chaisemartin C de, M Rivoire, B Trilling, M Jafari, G Portier, B Meunier, I Sieleznieff, M Bertrand, F Marchal, A Dubois, M Pocard, A Rullier, D Smith, N Frulio, E Frison, Q Denost, CC Fossum, JY Alabbad, LB Romak, CL Hallemeier, MG Haddock, M Huebner, EJ Dozois, DW Larson, J Simpson, JH Scholefield, L Feo, M Polcino, E Vinet, N Joharatnam-Hogan, W Wilson, KK Shiu, GK Fusai, B Davidson, D Hochhauser, J Bridgewater, K Khan, JY Luh, KV Albuquerque, C Cheng, RP Ermoian, N Nabavizadeh, H Parsai, JC Roeske, SE Weiss, RB Wynn, Y Yu, SA Rosenthal, A Hartford, S Gwynne, R Webster, R Adams, S Mukherjee, B Coles, J Staffurth, AC Hartford, JM Galvin, DC Beyer, TJ Eichler, GS Ibbott, B Kavanagh, CJ Schultz, ST Chao, LK Dad, LA Dawson, NB Desai, M Pacella, R Rengan, Y Xiao, KM Yenice, BS Teh, SY Woo, EB Butler, SS Lo, AJ Fakiris, EL Chang, NA Mayr, JZ Wang, L Papiez, RC McGarry, HR Cardenes, RD Timmerman, AB Sharabi, PT Tran, M Lim, CG Drake, TL Deweese, E Lavrova, MD Garrett, YF Wang, C Chin, C Elliston, M Savacool, M Price, LA Kachnic, DP Horowitz, KK Brock, CH Chiang, TY Chao, MY Huang, M Haque, MS Shakil, KM Mahmud, EJ Vaios, J Yan, C Wang, X Jiang, Y Wei, Q Wang, K Cui, X Xu, F Wang, L Zhang, T Mitin, AL Zietman, X Tian, K Liu, Y Hou, J Cheng, J Zhang, Y Hiroshima, H Ishikawa, M Murakami, M Nakamura, S Shimizu, T Enomoto, T Oda, M Mizumoto, K Nakai, T Okumura, H Sakurai, G Kraft, S Yamada, H Takiyama, Y Isozaki, M Shinoto, H Makishima, N Yamamoto, H Tsuji, DK Ebner, T Kamada, EG Chiorean, G Nandakumar, T Fadelu, S Temin, AE Alarcon-Rozas, S Bejarano, AE Croitoru, S Grover, PV Lohar, A Odhiambo, ER Garcia, C Teh, A Rose, B Zaki, MD Chamberlin, Dominguez O Hernandez, S Yilmaz, SR Steele, D Duarte, N Vale, XH You, YH Jiang, Z Fang, F Sun, Y Li, W Wang, ZJ Xia, XZ Wang, HQ Ying, L Xiong, Y Lou, L Wang, NN Baxter, EB Kennedy, E Bergsland, J Berlin, TJ George, S Gill, PJ Gold, A Hantel, L Jones, C Lieu, N Mahmoud, YN You, JA Meyerhardt, WJ Thompson, GA Piazza, H Li, L Liu, J Fetter, B Zhu, G Sperl, D Ahnen, R Pamukcu, BN Islam, DD Browning, M Cruz-Burgos, A Losada-Garcia, CD Cruz-Hernández, SA Cortés-Ramírez, I Camacho-Arroyo, V Gonzalez-Covarrubias, M Morales-Pacheco, SI Trujillo-Bornios, M Rodríguez-Dorantes, P Dent, L Booth, JL Roberts, A Poklepovic, JF Hancock, N Arber, CJ Eagle, J Spicak, I Rácz, P Dite, J Hajer, M Zavoral, MJ Lechuga, P Gerletti, J Tang, RB Rosenstein, K Macdonald, P Bhadra, R Fowler, J Wittes, SD Solomon, B Levin, J Peñarando, A Cañas, LM López-Sánchez, F Conde, S Guil-Luna, V Hernández, C Villar, C Morales-Estévez, la Haba-Rodríguez J de, E Aranda, A Rodríguez-Ariza, RK Phillips, MH Wallace, PM Lynch, E Hawk, GB Gordon, BP Saunders, N Wakabayashi, Y Shen, S Zimmerman, L Godio, M Rodrigues-Bigas, LK Su, J Sherman, G Kelloff, G Steinbach, CA Burke, R Phillips, JS Morris, R Slack, X Wang, S Patterson, FA Sinicrope, MA Rodriguez-Bigas, E Half, S Bulow, A Latchford, S Clark, WA Ross, B Malone, H Hasson, E Richmond, D Fina, L Franchi, R Caruso, I Peluso, GC Naccari, S Bellinvia, R Testi, F Pallone, G Monteleone, A Reinacher-Schick, A Schoeneck, U Graeven, I Schwarte-Waldhoff, W Schmiegel, C Stolfi, J Słoka, M Madej, B Strzalka-Mrozik, AF Slater, JH Choi, JS Yoon, YW Won, BB Park, YY Lee, K Sasaki, NH Tsuno, E Sunami, K Kawai, K Hongo, M Hiyoshi, M Kaneko, K Murono, N Tada, T Nirei, K Takahashi, J Kitayama, M Selvakumaran, RK Amaravadi, IA Vasilevskaya, PJ O'Dwyer, LE Anselmino, MV Baglioni, G Reynoso, VR Rozados, OG Scharovsky, MJ Rico, M Menacho-Márquez, T André, C Boni, L Mounedji-Boudiaf, M Navarro, J Tabernero, T Hickish, C Topham, M Zaninelli, P Clingan, I Tabah-Fisch, Gramont A de, A Bonetti, F Rivera, JP Kuebler, HS Wieand, MJ O'Connell, RE Smith, LH Colangelo, G Yothers, NJ Petrelli, MP Findlay, TE Seay, JN Atkins, JL Zapas, JW Goodwin, L Fehrenbacher, RK Ramanathan, BA Conley, PJ Flynn, G Soori, LK Colman, EA Levine, KS Lanier, N Wolmark, A Figer, M Seymour, M Homerin, A Hmissi, J Cassidy, H Cortes-Funes, G Freyer, D Papamichael, Bail N Le, C Louvet, D Hendler, Braud F de, C Wilson, F Morvan, A Mohammed, NB Janakiram, M Brewer, K Vedala, VE Steele, CV Rao, AR Brás, P Fernandes, T Moreira, J Morales-Sanfrutos, E Sabidó, AMM Antunes, A Valente, A Preto, C Teixeira-Guedes, RG Teixeira, Garcia M Helena, TS Morais, P Florindo, MF Piedade, V Moreno, C Ciudad, V Noe, YT Lee, YJ Tan, CE Oon, VV Padma, Z Koveitypour, F Panahi, M Vakilian, M Peymani, Forootan F Seyed, Esfahani MH Nasr, K Ghaedi, N Valeri, C Dearman, S Rao, D Watkins, N Starling, I Chau, D Cunningham, J Neumann, L Wehweck, S Maatz, J Engel, T Kirchner, A Jung, Y Humblet, S Siena, D Khayat, H Bleiberg, A Santoro, D Bets, M Mueser, A Harstrick, C Verslype, Cutsem E Van, G Fornasier, S Francescon, P Baldo, CH Köhne, E Hitre, J Zaluski, Chien CR Chang, A Makhson, G D'Haens, T Pintér, R Lim, G Bodoky, JK Roh, G Folprecht, P Ruff, C Stroh, S Tejpar, M Schlichting, J Nippgen, P Rougier, I Láng, MP Nowacki, S Cascinu, I Shchepotin, J Maurel, A Zubel, I Celik, F Ciardiello, TS Maughan, RA Adams, CG Smith, AM Meade, MT Seymour, RH Wilson, S Idziaszczyk, R Harris, D Fisher, SL Kenny, E Kay, JK Mitchell, A Madi, B Jasani, MD James, MJ Kennedy, B Claes, D Lambrechts, R Kaplan, JP Cheadle, CJ Allegra, RB Rumble, SR Hamilton, PB Mangu, N Roach, RL Schilsky, VK Morris, AB 3rd Benson, M Cho, KK Ciombor, C Cremolini, A Davis, DA Deming, MG Fakih, S Gholami, TS Hong, I Jaiyesimi, K Klute, H Sanoff, JH Strickler, S White, JA Willis, C Eng, F Petrelli, R Ardito, A Ghidini, A Zaniboni, M Ghidini, S Barni, G Tomasello, L Lo, D Patel, AR Townsend, TJ Price, JY Douillard, R Burkes, M Barugel, J Jassem, I Kocákova, M Błasińska-Morawiec, M Šmakal, JL Canon, M Rother, KS Oliner, M Wolf, J Gansert, TW Kim, A Elme, JO Park, AA Udrea, SY Kim, JB Ahn, RV Valencia, S Krishnan, N Manojlovic, X Guan, C Lofton-Day, AS Jung, E Vrdoljak, D Rossini, A Boccaccino, M Carullo, C Antoniotti, G Dima, P Ciracì, F Marmorino, R Moretto, G Masi, T Liu, S Jiang, X Teng, L Zhong, M Liu, Y Jin, M Dong, Y Zhang, JY Zou, Y Wang, A Dasari, S Lonardi, R Garcia-Carbonero, E Elez, T Yoshino, A Sobrero, J Yao, P García-Alfonso, J Kocsis, Gracian A Cubillo, A Sartore-Bianchi, T Satoh, V Randrian, J Tomasek, G Chong, AS Paulson, T Masuishi, J Jones, T Csőszi, F Ghiringhelli, A Shergill, HS Hochster, J Krauss, A Bassam, M Ducreux, L Faugeras, S Kasper, D Arnold, S Nanda, Z Yang, WR Schelman, M Kania, D Dakowicz, R Bhattacharya, XC Ye, R Wang, X Ling, M McManus, F Fan, D Boulbes, LM Ellis, X Ye, L Xia, J Garcia, HI Hurwitz, AB Sandler, D Miles, RL Coleman, R Deurloo, OL Chinot, H Hurwitz, W Novotny, T Cartwright, J Hainsworth, W Heim, A Baron, S Griffing, E Holmgren, N Ferrara, G Fyfe, B Rogers, R Ross, F Kabbinavar, C Zhang, Y Lv, C Cao, J Lu, B Du, X Yang, Y Cui, Y Guo, R Lakomy, H Prenen, J Prausová, T Macarulla, Hazel GA van, V Moiseyenko, D Ferry, J McKendrick, J Polikoff, A Tellier, R Castan, C Allegra, A Thakur, MR Chorawala, RS Patel, AL Cohn, R Obermannova, TE Ciuleanu, DC Portnoy, A Grothey, P Garcia-Alfonso, K Yamazaki, PR Clingan, L Simms, SC Chang, F Nasroulah, P Ge, N Wan, X Han, X Long, Y Bian, Z Gao, Y Bao, Y Fan, G Chen, P Fu, J Ros, M Rodríguez-Castells, N Saoudi, I Baraibar, F Salva, E Élez, H Wasan, J Desai, F Loupakis, YS Hong, N Steeghs, TK Guren, HT Arkenau, A Gollerkeri, K Maharry, J Christy-Bittel, S Kopetz, DY Oh, YJ Bang, SJ Casak, MN Horiba, M Yuan, SJ Lemery, YL Shen, W Fu, JN Moore, Y Bi, D Auth, N Fesenko, PG Kluetz, R Pazdur, LA Fashoyin-Aje, T Vu, FX Claret, K Ng, C Wu, JM Hubbard, AL Coveler, C Fountzilas, A Kardosh, PM Kasi, HJ Lenz, DL Bajor, F Sanchez, M Stecher, W Feng, TS Bekaii-Saab, J Koury, M Lucero, C Cato, L Chang, J Geiger, D Henry, J Hernandez, F Hung, P Kaur, G Teskey, A Tran, Z Zhang, AS Shimu, HX Wei, Q Li, X Zheng, B Li, J Zheng, DM Pardoll, Y Shiravand, F Khodadadi, SMA Kashani, SR Hosseini-Fard, S Hosseini, H Sadeghirad, R Ladwa, K O'Byrne, A Kulasinghe, JA Seidel, A Otsuka, K Kabashima, HB Jie, Y Lei, N Gildener-Leapman, S Trivedi, T Green, LP Kane, RL Ferris, ME Keir, MJ Butte, GJ Freeman, AH Sharpe, M Wu, Q Huang, Y Xie, X Wu, H Ma, Y Xia, for Colorectal Cancer Immunotherapy, C for DE Research, LA Jr Diaz, BV Jensen, LH Jensen, C Punt, M Benavides, P Gibbs, la Fourchardiere C de, DT Le, WY Zhong, D Fogelman, P Marinello, T Andre, F Hirano, K Kaneko, H Tamura, H Dong, M Ichikawa, C Rietz, DB Flies, JS Lau, G Zhu, K Tamada, L Chen, MJ Overman, R McDermott, JL Leach, MA Morse, A Hill, M Axelson, RA Moss, MV Goldberg, ZA Cao, JM Ledeine, GA Maglinte, O Kooshkaki, A Derakhshani, N Hosseinkhani, M Torabi, S Safaei, O Brunetti, V Racanelli, N Silvestris, B Baradaran, V Singh, A Sheikh, MAS Abourehab, P Kesharwani, A GSK, M Lumish, J Sinopoli, J Weiss, M Lamendola-Essel, Dika IH El, N Segal, M Shcherba, R Sugarman, Z Stadler, B Rousseau, G Argiles, M Patel, A Desai, M Widmar, K Iyer, N Gianino, C Crane, PB Romesser, EP Pappou, P Paty, M Gollub, KA Schalper, T Watanabe, T Ishino, Y Ueda, J Nagasaki, T Sadahira, H Dansako, M Araki, Y Togashi, S Hashemzadeh, Z Asadzadeh, MA Shadbad, F Rasibonab, H Safarpour, V Jafarlou, AG Solimando, PK Singh, S Najafi, D Javadrashid, A Tarhini, KYM Wong, F Gelsomino, M Aglietta, MB Sawyer, A Hendlisz, B Neyns, S Abdullaev, A Memaj, M Lei, M Dixon, PM Boland, WW Ma, CH June, SR Riddell, TN Schumacher, A Mitra, A Barua, L Huang, S Ganguly, Q Feng, B He, H Du, J Yang, Q Zhang, J Shen, X Huang, M Wang, Y Huang, J Chen, Y Xu, W Zhao, Y Qi, Y Ou, C Qian, DJ Juat, SJ Hachey, J Billimek, Rosario MP Del, EL Nelson, CCW Hughes, JA Zell, E Martinis, C Ricci, C Trevisan, G Tomadini, S Tonon, Z Wu, M Yang, Y Cao, W Jia, T Zhang, H Huang, H Feng, Z Guo, Z Luo, X Ji, X Cheng, R Zhao, E Janssen, B Subtil, la Jara Ortiz F de, HMW Verheul, DVF Tauriello, Therapeutics Tizona, LLC Inc, Sankyo Co Daiichi, SE BioNTech, DS Neel, TG Bivona, A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, E Scala, A Cassingena, D Zecchin, M Apicella, G Migliardi, F Galimi, C Lauricella, C Zanon, T Perera, S Veronese, G Corti, A Amatu, M Gambacorta, M Sausen, VE Velculescu, P Comoglio, L Trusolino, Nicolantonio F Di, S Giordano, A Jahangiri, Lay M De, LM Miller, WS Carbonell, YL Hu, K Lu, MW Tom, J Paquette, TA Tokuyasu, S Tsao, R Marshall, A Perry, KM Bjorgan, MM Chaumeil, SM Ronen, G Bergers, MK Aghi, CJ LaFargue, P Amero, K Noh, LS Mangala, Y Wen, E Bayraktar, S Umamaheswaran, E Stur, SK Dasari, C Ivan, S Pradeep, W Yoo, C Lu, NB Jennings, V Vathipadiekal, W Hu, A Chelariu-Raicu, Z Ku, H Deng, W Xiong, HJ Choi, M Hu, T Kiyama, CA Mao, R Ali-Fehmi, MJ Birrer, N Zhang, G Lopez-Berestein, Franciscis V de, Z An, AK Sood, M Hao, S Hou, W Li, K Li, L Xue, Q Hu, L Zhu, Y Chen, H Sun, C Ju, YL Tang, DD Li, JY Duan, LM Sheng, J Manzi, CO Hoff, R Ferreira, A Pimentel, J Datta, AS Livingstone, R Vianna, P Abreu, GM Ramzy, M Norkin, T Koessler, L Voirol, M Tihy, D Hany, T McKee, N Buchs, M Docquier, C Toso, L Rubbia-Brandt, G Bakalli, S Guerrier, J Huelsken, P Nowak-Sliwinska, JD Fumet, A Hoos, AM Eggermont, S Janetzki, FS Hodi, R Ibrahim, A Anderson, R Humphrey, B Blumenstein, L Old, J Wolchok, F Tartari, M Santoni, L Burattini, P Mazzanti, A Onofri, R Berardi, J Zugazagoitia, C Guedes, S Ponce, I Ferrer, S Molina-Pinelo, L Paz-Ares, Velzen MJM van, S Derks, Grieken NCT van, Mohammad N Haj, Laarhoven HWM van, N Huyghe, P Baldin, den Eynde M Van, G Trimaglio, AF Tilkin-Mariamé, V Feliu, F Lauzéral-Vizcaino, M Tosolini, C Valle, M Ayyoub, O Neyrolles, N Vergnolle, Y Rombouts, C Devaud, AD Kostic, E Chun, L Robertson, JN Glickman, CA Gallini, M Michaud, TE Clancy, DC Chung, P Lochhead, GL Hold, EM El-Omar, D Brenner, CS Fuchs, M Meyerson, WS Garrett, LS Pessoa, M Heringer, VP Ferrer, Maghvan P Vaseghi, S Jeibouei, ME Akbari, V Niazi, F Karami, A Rezvani, N Ansarinejad, M Abbasinia, G Sarvari, H Zali, R Talaie, A Dey, S Pathak, S Prasad, AS Zhang, H Zhang, XF Sun, A Banerjee Show less
Colorectal cancer (CRC) is the third most common cancer worldwide, and the second most common cause of cancer-related death. In 2020, the estimated number of deaths due to CRC was approximately 930000 Show more
Colorectal cancer (CRC) is the third most common cancer worldwide, and the second most common cause of cancer-related death. In 2020, the estimated number of deaths due to CRC was approximately 930000, accounting for 10% of all cancer deaths worldwide. Accordingly, there is a vast amount of ongoing research aiming to find new and improved treatment modalities for CRC that can potentially increase survival and decrease overall morbidity and mortality. Current management strategies for CRC include surgical procedures for resectable cases, and radiotherapy, chemotherapy, and immunotherapy, in addition to their combination, for non-resectable tumors. Despite these options, CRC remains incurable in 50% of cases. Nonetheless, significant improvements in research techniques have allowed for treatment approaches for CRC to be frequently updated, leading to the availability of new drugs and therapeutic strategies. This review summarizes the most recent therapeutic approaches for CRC, with special emphasis on new strategies that are currently being studied and have great potential to improve the prognosis and lifespan of patients with CRC. Show less
📄 PDF DOI: 10.5306/wjco.v15.i9.1136
review
Jong-Lyel Roh, Eun Hye Kim, Hyejin Jang +1 more · 2017 · Redox biology · Elsevier · added 2026-04-20
UNLABELLED: Artesunate, an anti-malarial drug, has been repurposed as an anticancer drug due to its induction of cell death via reactive oxygen species (ROS) production. However, the molecular mechani Show more
UNLABELLED: Artesunate, an anti-malarial drug, has been repurposed as an anticancer drug due to its induction of cell death via reactive oxygen species (ROS) production. However, the molecular mechanisms regulating cancer cell death and the resistance of cells to artesunate remain unclear. We investigated the molecular mechanisms behind the antitumor effects of artesunate and an approach to overcome artesunate resistance in head and neck cancer (HNC). The effects of artesunate and trigonelline were tested in different HNC cell lines, including three cisplatin-resistant HNC cell lines. The effects of these drugs as well as the inhibition of Keap1, Nrf2, and HO-1 were assessed by cell viability, cell death, glutathione (GSH) and ROS production, protein expression, and mouse tumor xenograft models. Artesunate selectively killed HNC cells but not normal cells. The artesunate sensitivity was relatively low in cisplatin-resistant HNC cells. Artesunate induced ferroptosis in HNC cells by decreasing cellular GSH levels and increasing lipid ROS levels. This effect was blocked by co-incubation with ferrostatin-1 and a trolox pretreatment. Artesunate activated the Nrf2-antioxidant response element (ARE) pathway in HNC cells, which contributed to ferroptosis resistance. The silencing of Keap1, a negative regulator of Nrf2, decreased artesunate sensitivity in HNC cells. Nrf2 genetic silencing or trigonelline reversed the ferroptosis resistance of Keap1-silenced and cisplatin-resistant HNC cells to artesunate in vitro and in vivo. Nrf2-ARE pathway activation contributes to the artesunate resistance of HNC cells, and inhibition of this pathway abolishes ferroptosis-resistant HNC. CONDENSED ABSTRACT: Our results show the effectiveness and molecular mechanism of artesunate treatment on head and neck cancer (HNC). Artesunate selectively killed HNC cells but not normal cells by inducing an iron-dependent, ROS-accumulated ferroptosis. However, this effect may be suboptimal in some cisplatin-resistant HNCs because of Nrf2-antioxidant response element (ARE) pathway activation. Inhibition of the Nrf2-ARE pathway increased artesunate sensitivity and reversed the ferroptosis resistance in resistant HNC cells. Show less
no PDF DOI: 10.1016/j.redox.2016.12.010
Co Fe ROS amino-acid anticancer
Eun Hye Kim, Hyejin Jang, Daiha Shin +2 more · 2016 · Apoptosis : an international journal on programmed cell death · Springer · added 2026-04-20
A principal limitation to the clinical use of cisplatin is the high incidence of chemoresistance to this drug. Combination treatments with other drugs may help to circumvent this problem. Wogonin, one Show more
A principal limitation to the clinical use of cisplatin is the high incidence of chemoresistance to this drug. Combination treatments with other drugs may help to circumvent this problem. Wogonin, one of the major natural flavonoids, is known to reverse multidrug resistance in several types of cancers. We investigated the ability of wogonin to overcome cisplatin resistance in head and neck cancer (HNC) cells and further clarified its molecular mechanisms of action. Two cisplatin-resistant HNC cell lines (AMC-HN4R and -HN9R) and their parental and other human HNC cell lines were used. The effects of wogonin, either alone or in combination with cisplatin, were assessed in HNC cells and normal cells using cell cycle and death assays and by measuring cell viability, reactive oxygen species (ROS) production, and protein expression, and in tumor xenograft mouse models. Wogonin selectively killed HNC cells but spared normal cells. It inhibited nuclear factor erythroid 2-related factor 2 and glutathione S-transferase P in cisplatin-resistant HNC cells, resulting in increased ROS accumulation in HNC cells, an effect that could be blocked by the antioxidant N-acetyl-L-cysteine. Wogonin also induced selective cell death by targeting the antioxidant defense mechanisms enhanced in the resistant HNC cells and activating cell death pathways involving PUMA and PARP. Hence, wogonin significantly sensitized resistant HNC cells to cisplatin both in vitro and in vivo. Wogonin is a promising anticancer candidate that induces ROS accumulation and selective cytotoxicity in HNC cells and can help to overcome cisplatin-resistance in this cancer. Show less
no PDF DOI: 10.1007/s10495-016-1284-8
ROS amino-acid anticancer